Avalo Therapeutics, Inc.
NASDAQ:AVTX · NASDAQ Capital Market
-$0.34 today
Vol 6.42M · Avg 1.61M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+206.89%
Period High
$22.87
Period Low
$4.75
Latest
$14.70
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$332.83M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$293.92M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$234.13M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$213.27M
Inventiva S.A.
NASDAQ:IVA
$184.04M
Coherus Oncology, Inc.
NASDAQ:CHRS
$173.21M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.21M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.47M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$93.69M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$86.59M
What is the latest AVTX filing?
The latest filing shown is 8-K dated Jun 16, 2026.
How many recent filings does AVTX have?
Intrinsic Alpha currently shows 20 recent filings for AVTX.
Explore More
Continue the stock analysis
Jump to another research area for this company.